BridgeMD
New treatment option for Parkinson Disease (PD)
Official title Effects of Transcranial Direct Current Stimulation Combined With Nordic Walking on Gait and Balance in Parkinson's Disease
ClinicalTrials.gov ID: NCT07381907
What this study is testing
- What it's testing
- Parkinson's disease can cause slow or unsteady walking and balance problems that raise the risk of falls. This study will test whether adding a gentle, non-invasive brain stimulation called transcranial direct current stimulation (tDCS) during a supervised Nordic Walking program improves mobility in people with Parkinson's disease.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 50 to 75
You may be able to join if
- Idiopathic Parkinson's disease (e.g., UK Brain Bank criteria)
- Hoehn \& Yahr stage II-IV (on medication)
- Stable antiparkinsonian medication for ≥4 weeks before enrollment
- Slowed gait phenotype (e.g., ≥6 seconds on 10-Meter Walk at preferred speed)
- Able to ambulate at least 10 meters with or without a cane/poles (no hands-on assistance from a therapist)
You likely can't join if
- Contraindications to tDCS: implanted cranial/brain devices (e.g., DBS), metal in the skull (excluding dental), active skin disease/lesions at...
- Unstable medical or psychiatric conditions that preclude safe participation (e.g., uncontrolled hypertension, recent cardiovascular events, severe...
- Severe freezing of gait or fall risk that prevents safe participation in supervised Nordic Walking, as judged by the clinical team
- Severe musculoskeletal or vestibular disorders that limit walking with poles; severe uncorrected visual impairment
- Cognitive impairment incompatible with consent or testing (e.g., MMSE \<24)
- Current participation in other treatment trials targeting gait/balance or brain stimulation; recent initiation or dose change of antiparkinsonian...
See the full eligibility criteria
- Idiopathic Parkinson's disease (e.g., UK Brain Bank criteria)
- Hoehn \& Yahr stage II-IV (on medication)
- Stable antiparkinsonian medication for ≥4 weeks before enrollment
- Slowed gait phenotype (e.g., ≥6 seconds on 10-Meter Walk at preferred speed)
- Able to ambulate at least 10 meters with or without a cane/poles (no hands-on assistance from a therapist)
- Able to follow simple commands; provides written informed consent (MMSE ≥24 or equivalent cognitive screening)
- Willing to maintain stable PD medication and usual care during the 4-week intervention, unless medically required
- Contraindications to tDCS: implanted cranial/brain devices (e.g., DBS), metal in the skull (excluding dental), active skin disease/lesions at electrode sites, uncontrolled epilepsy or history of seizure in the past 12...
- Unstable medical or psychiatric conditions that preclude safe participation (e.g., uncontrolled hypertension, recent cardiovascular events, severe orthostatic hypotension with syncope)
- Severe freezing of gait or fall risk that prevents safe participation in supervised Nordic Walking, as judged by the clinical team
- Severe musculoskeletal or vestibular disorders that limit walking with poles; severe uncorrected visual impairment
- Cognitive impairment incompatible with consent or testing (e.g., MMSE \<24)
- Current participation in other treatment trials targeting gait/balance or brain stimulation; recent initiation or dose change of antiparkinsonian medication within 4 weeks.
The study team makes the final eligibility decision.
Where it's taking place
- Belém, Pará, Brazil
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 50 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Belém, Pará, Brazil. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.